$Bob's and Jbem's Bitchin' Bios

[BioSpecialist]

IGXT ($46 M) 2 NDA Submission within 2 months this will make IGXT as one of the most attractive and underpriced fda play you can get at this time .


Market Cap $46 Million
Cash untill 2021+ (including convertible debt)
Price: 0.70

Patent ruling regarding Par project this month
NDA submission for tadalafil in June or July
NDA resubmission for Rizaport in early Q3
Partnership for Tadalafil in 2H 2017


Most people still not realize the signifance of this news below ..Tadalafil could be up to 2 years on market before the generics enter the Market THATS MEGA NEWS for Intelgenx they will earn a lot of money .

http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.



http://s2.q4cdn.com/790425727/files/doc_financials/2017/Q1/final-051117-intelgenx-corp-q1-2017-financial-results-18899915.pdf

The trial with the ANDA applicants that submitted applications for generic copies, is scheduled for July. Some of the ANDA applicants have already settled with Lilly, settled in the sense that they have greed to launch their generic product only at the expiry of this third patent, the dosing patent that we obtained a license for. That means that we have a pretty good chance to enjoy an extended period of excessivity once we’ve launched our product. Several companies have expressed interest in licensing the product. Term sheets(phon)have been submitted and are currently being reviewed and the due-diligence process has commenced.

Now a few words on our Par project for the indication of opioids dependency. That product is entirely driven by litigation. We had a paragraph 4 case ongoing last year, and as we reported previously, we won on two patents and lost on a third patent. In addition, there was a court proceeding in November of last year on a non-Orange Book patent. We expect the ruling on that case and on that patent very soon in June.